Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex (VERX) announced the expansion of its Chief Strategy Office with the addition of Christopher Hall and Kathya Capote Peimbert. Their ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same ...